- MarketWatch•1 hour ago
One catalyst: Big drug companies are running out of ideas, writes Michael Brush.
- Investor's Business Daily•3 days ago
The biotech industry has a mixed outlook, but Incyte is one of the few companies with potential blockbuster drugs in its pipeline.
- Investor's Business Daily•4 days ago
Barclays analyst Geoff Meacham on Thursday said he expected Gilead Sciences' 2017 outlook to be hindered on limited hepatitis C sales.
INCY : Summary for Incyte Corporation - Yahoo Finance
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||118.03 x 300|
|Ask||118.28 x 100|
|Day's Range||117.77 - 118.82|
|52 Week Range||55.00 - 122.68|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||321.25|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|